Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ACADEMIA
ACADEMIA
- Japan Hypertension Society to Retract Diovan Paper on VART Study
August 16, 2016
- Japan Society Draws Up New Guidelines on Depression
August 16, 2016
- 3 Scientific Societies to Set Up HBOC Body to Build BRCA Gene Database
August 4, 2016
- Scientific Panel Fails to Reach Consensus on Withdrawal of Antiresorptive Agents Before Oral Invasive Surgery
July 27, 2016
- New Enuresis Treatment Guidelines Recommend Desmopressin as First-Line Pharmacotherapy: Japanese Society on Enuresis
July 26, 2016
- Regenerative Medicine Society to Introduce Treatment Compensation System in November
July 26, 2016
- Japanese Society of Nephrology Aims to Promote Development through “Surrogate Endpoints”; Hopes to Draft Guidelines in FY2017
July 22, 2016
- 1st Line Statins Likely to Be Recommended for Pediatric Familial Hypercholesterolemia
July 21, 2016
- New Atherosclerosis Guidelines Likely to Add PCSK9 Inhibitors for Primary Prevention of CAD in Familial Hypercholesterolemia
July 20, 2016
- Japan Oncology Society Warns of Privately Imported Opdivo, Yervoy
July 19, 2016
- JSGO Will Revise Guidelines to Recommend Bevacizumab in Treatment of Stage IVB/Relapsed Cervical Cancer
July 14, 2016
- Biosimilar Use Should Be Required Under Publicly Funded Systems: JSGM Pres.
July 13, 2016
- Japan Esophageal Society to Recommend 5-FU + Cisplatin as 1st-Line Therapy for Esophageal Cancer in New Guidelines
July 7, 2016
- MHLW Working Group Drafting Guidelines for Development of Cell Therapies for Cerebral Infarction
July 4, 2016
- Accelerate Investigator-Initiated Trials to Promote Academia-Led Drug Discovery: New NCGM Research Center Chief
July 1, 2016
- 865,238 People Diagnosed with Cancer in 2012: NCC
June 30, 2016
- MHLW Study Group Aims to Formulate Guidelines for Treatment of Skeletal Dysplasias in FY2017
June 29, 2016
- Nexium, Takecab Added to Standard Treatments for 1st Eradication of H. Pylori: JSHR Guidelines
June 28, 2016
- PD-1’s “Actual Physiology Remains Unclear”: Discoverer of PD-1
June 21, 2016
- No Increased Mortality Risks Seen in Japanese AD Patients on Antipsychotics: Study
June 17, 2016
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…